MarketsandMarkets BioProduction Manufacturing Crystal Ball Event

Grab before it's gone. Avail 30% Instant Discount

Look what we found for you. Use the code to avail 30% instant discount across all delegate participation opportunities. Get a chance to network with industry leaders and key decision makers. Learn from the best. Grow your knowledge exponentially.

Please fill up the Enquiry Form to reveal the code.

High growth markets which contribute to 20% of your revenues today will contribute 80% in the next 5 years. Identify these new revenue sources at MarketsandMarkets’s Crystal Ball event

High growth markets which contribute to 20% of your revenues today will contribute 80% in the next 5 years. Identify these new revenue sources at MarketsandMarkets’ s Crystal Ball event

The end product sales in bioproduction market are expected to grow at over `15% to be a $305 Bn market in 2025. Numerous engines are expected to fuel its growth – Cell Therapy, Gene Therapy, Monoclonal Antibodies, Vaccines, biosimilars and bio betters, plasma therapy as well as others.

A host of attractive, high growth opportunities such as single use systems, Lab Scale and CGMP manufacturing and R&D, Crispr and other Gene editing tools and technologies, Novel downstream bioprocessing methods etc. could be pursued. Participants such as CROs, CMOs, Bioprocess solutions manufacturers, Biobanks, automation technology providers etc. can benefit from this unprecedented growth over the next 5 years.

This Crystal Ball event focuses on learning more about the most promising opportunities in the Bioproduction ecosystem, as seen through the lens of eminent CXOs in this space

What to Expect

Key
Highlights

Continuous biomanufacturing is expected to double in the next 5 years, garnering larger share from conventional batch processing.
Alternative and Novel downstream bioprocessing techniques generate a significant share of over $16 billion growth overall.
Increasing demand for major end products led by monoclonal antibodies, vaccines, biosimilars, bio betters, plasma therapy, cell & gene therapy, and human microbiome therapeutics, are growing at 3 times the rate of conventional therapeutics.

Crystal Ball:
Through the Speakers Perspective

How can Cell therapy market expand faster in non-oncology indications & out of US and how can this transition be expedited?
Which technologies can result in the improvement of production yields and optimize supply chain of COVID-19 vaccine?
Why is the mRNA vaccine approval so pivotal for the future of disease therapeutics?
What could be characteristics for an ideal biotech innovator &CROs/CMOs cooperation for accelerating development and commercialization of cell-based therapeutics?

Conference Agenda

Top 10 disruptions in Biopharma Manufacturing

90 minutes of brainstorming among 4 great minds which will aim at bringing out a tangible action plan by discussing the question given below:

What are the top 10 revenue growth opportunities for bioproduction ecosystem participants over the next 5 years? Which markets, technologies, customer segments ate the most attractive to place bets?
What could be characteristics for an ideal biotech innovator &CROs/CMOs cooperation for accelerating development and commercialization of cell-based therapeutics?
Which technologies/approaches are likely to result in the improvement or optimization of production yields, timeline, and supply chain of COVID-19 vaccines?
How can Cell therapy market expand faster in non-oncology indications & out of US and how can this transition be expedited?
Will accelerated mRNA vaccine approvals for COVID-19 act as being pivotal/inflection point for the future of RNA Based/targeted therapeutics?
Single-use systems are thought to increase flexibility and reduce production lead times, while lowering capital investment and energy requirements. Can they help cater to increased sophistication in production requirements of personalized or targeted therapeutics?